GlassScriptPhysician profile
Bharat Dasani
NPI 1073698049
$15,725.72
in general payments reported to CMS, 2019-2025
33 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $424 · 2021: $2,854 · 2022: $1,123 · 2023: $5,831 · 2024: $2,039 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,321 · Debt Forgiveness: $4,265 · Education: $16.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,321.12 |
| Debt Forgiveness | $4,265.00 |
| Education | $16.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $4,265.00 | 2023 | |
| Redhill Biopharma INC. | $2,093.06 | 2020-2025 | Talicia, Aemcolo, Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,282.22 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $1,264.85 | 2020-2025 | Linzess, Creon, Viberzi |
| E.R. Squibb & Sons, L.L.C. | $857.22 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $773.61 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $664.39 | 2019-2025 | |
| Intra-Sana Laboratories | $614.36 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Madrigal Pharmaceuticals | $529.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $515.31 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $494.68 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $421.35 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $247.68 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $225.34 | 2019-2024 | Dificid |
| Ardelyx, INC. | $213.29 | 2024-2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $185.39 | 2020-2023 | |
| Gilead Sciences, INC. | $177.01 | 2019-2022 | |
| Braintree Laboratories, INC. | $163.86 | 2020-2024 | Suflave, Sutab |
| Medtronic, INC. | $148.80 | 2023 | Interstim |
| Novo Nordisk INC | $121.15 | 2025 | Wegovy |
| Ethicon US, LLC | $92.56 | 2019 | |
| Echosens North America, INC. | $64.68 | 2024 | Fibroscan |
| Ferring Pharmaceuticals INC. | $55.40 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $48.47 | 2024-2025 | Zenpep |
| Abbott Laboratories | $41.09 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $39.76 | 2025 | Kristalose |
| Intercept Pharmaceuticals, INC. | $27.79 | 2020 | |
| Alfasigma USA, INC. | $24.62 | 2020 | |
| Celltrion USA INC. | $16.38 | 2024 | Zymfentra |
| Boston Scientific Corporation | $15.63 | 2025 | Radial Jaw 4 |
| Allergan, INC. | $14.69 | 2019 | |
| Shionogi INC | $14.06 | 2019 | |
| Celgene Corporation | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bharat Dasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.